- Home
- ATOS vs PLX Comparison
ATOS vs PLX Comparison
Compare ATOS & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- PLX
- Stock Information
- Founded
- ATOS 2009
- PLX 1993
- Country
- ATOS United States
- PLX United States
- Employees
- ATOS N/A
- PLX N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATOS Health Care
- PLX Health Care
- Exchange
- ATOS Nasdaq
- PLX Nasdaq
- Market Cap
- ATOS 107.2M
- PLX 127.4M
- IPO Year
- ATOS 2012
- PLX 1998
- Fundamental
- Price
- ATOS $0.84
- PLX $1.82
- Analyst Decision
- ATOS Strong Buy
- PLX Strong Buy
- Analyst Count
- ATOS 3
- PLX 1
- Target Price
- ATOS $6.17
- PLX $15.00
- AVG Volume (30 Days)
- ATOS 483.0K
- PLX 672.9K
- Earning Date
- ATOS 11-11-2025
- PLX 11-13-2025
- Dividend Yield
- ATOS N/A
- PLX N/A
- EPS Growth
- ATOS N/A
- PLX N/A
- EPS
- ATOS N/A
- PLX 0.08
- Revenue
- ATOS N/A
- PLX $61,948,000.00
- Revenue This Year
- ATOS N/A
- PLX $14.53
- Revenue Next Year
- ATOS N/A
- PLX $75.77
- P/E Ratio
- ATOS N/A
- PLX $23.37
- Revenue Growth
- ATOS N/A
- PLX 62.79
- 52 Week Low
- ATOS $0.55
- PLX $0.99
- 52 Week High
- ATOS $1.66
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- ATOS 60.84
- PLX 66.24
- Support Level
- ATOS $0.81
- PLX $1.52
- Resistance Level
- ATOS $0.80
- PLX $1.69
- Average True Range (ATR)
- ATOS 0.03
- PLX 0.08
- MACD
- ATOS 0.01
- PLX 0.02
- Stochastic Oscillator
- ATOS 92.67
- PLX 92.31
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.